OVERVIEW | FOUNDING DIRECTORS | CORPORATE DIRECTORY | STATUTORY DETAILS

 
Company Profile

Infexion is focussed on breakthrough treatments for infectious diseases.

Our strategic aim is that:
“Infexion will be a leading global research based company in infectious disease therapies by 2012”

Infexion is a division of Proxima Concepts Limited, whom have been working in the fields of drug delivery and discovery since 2000.

Business Model

Infexion’s business model is essentially simple and can be described as follows:

  • Outsourcing of non-essential functions.
  • Minimisation of organisational overheads.
  • Combine in-house research with academic collaborations to expand portfolio.
  • Absolute commitment to good corporate governance and scientific practices.
  • Out-licence products in Phase 2 of development.
  • Reserve certain co-promotional rights where appropriate to build a future specialist sales capability.
  • Use the global capital markets to finance progress.